Report Overview

The global monoclonal antibody therapy market was pegged at US$ 175.5 billion in 2021 and is expected to witness a CAGR of 12.9% during the forecast period.

Market Fundamentals 

Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) which bind specifically to certain antigens. The main objective of this therapy is to stimulate the patient’s immune system to defend the foreign bodies. Monoclonal antibodies are used in the treatment of certain conditions such as cancer, autoimmune diseases such as rheumatoid arthritis, colitis, and Crohn’s disease, and in the treatment of Alzheimer’s disease. Because of their unique site-specificity characteristic, monoclonal antibodies are widely used in biochemistry, molecular biology, and medicine, as a tool to detect or purify substances. 

[12121212]

Market Dynamics

The increasing prevalence of cancer is one of the factors driving the monoclonal antibody therapy market. Cancer poses an immense cost burden globally, and governments are trying to reduce this annual healthcare cost on economies. Thus, there is an increased demand for biologics which is a great opportunity for the biopharmaceutical industry. Monoclonal antibodies are being approved favorably by regulatory bodies, which in turn is favoring the launch of many innovative therapeutics. This factor attributes to the growth of the monoclonal antibody therapy market. Since monoclonal antibody therapy is making an appearance as a powerful tool for the treatment of chronic diseases like cancer, rheumatoid arthritis, and Alzheimer’s disease, their preference is also rising. Thus, many pharmaceutical companies are investing in R&D activities. The combination of other therapy with monoclonal antibodies also drives this market. Furthermore, the use of advanced technology in mAb production, improved healthcare infrastructure, and support of the government in infection control and management further fuel the market. However, low demand in middle- and low-income countries due to unaffordability can restrain the market. Loss of patents also hampers the market.

Market Ecosystem

The global monoclonal antibody therapy market has been analyzed from five perspectives: type, disease area, production type, end-users, and region. 

Monoclonal Antibody Therapy Market by Type

[5643343]

Based on type, the market has been segmented into human mAb, chimeric mAb, humanized mAb, and murine mAb. The human mAb is in the dominating position in the global mAb therapy market. This dominance is because of the high demand for Humira antibody, which is used in the treatment of various conditions such as ulcerative colitis, arthritis, and Crohn’s disease. It was the first approved monoclonal antibody by FDA. Also, the rise in technological amalgamation for human mAb drives the market. The humanized antibody segment is expected to observe a surge in the forecast period because of increased funding in research by pharmaceutical companies and the rising number of humanized mAb therapies. 

Monoclonal Antibody Therapy Market by Disease Area

The cancer segment holds the major revenue share of the monoclonal antibody therapy market because of the increased incidence of cancer cases and increased adoption of this therapy along with huge investments in research activities. Also, the autoimmune diseases segment is expected to grow in the forecast period because of the increasing cases of rheumatoid arthritis, and Crohn’s disease, and its increased adoption for the treatment of these conditions. 

Monoclonal Antibody Therapy Market by Production Type

Monoclonal antibodies are produced are either in vitro or in vivo. Since in vivo technique is more cost-effective than in vitro it is the most preferred and hence dominates the market currently. However, the relatively low cost of in vitro methods, time efficiency, and more availability are expected to surge in the forecast period. 

Monoclonal Antibody Therapy Market by End User

Based on end-users, the monoclonal antibody therapy market has been segmented into hospitals, research clinics, and others. The hospital segment accounts for the highest revenue in the market due to the increased prevalence of nosocomial cases in the recent years. In addition, the manufacturers of these therapeutics are managing to expand the access of their products to as many hospitals and patients as possible to meet their higher demands, which will contribute to the growth of the segment and increase revenues in the global monoclonal antibody therapy market during the forecast period.

Monoclonal Antibody Therapy Market by Region

Based on region, the global monoclonal antibody therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). Due to its developed healthcare system, North America held the largest share in the market. Additionally, it is projected that over the forecast period, increased government support for technology development and cancer research will accelerate the creation of therapeutic proteins. Other significant drivers of this sector's expansion include the expanding population, increased prevalence of diseases linked to a sedentary lifestyle, and government support for infection prevention and management.

Competitive Landscape

Some of the prominent players operating in the monoclonal antibody therapy market are 

• F. Hoffman-La Roche Ltd
• Bayer AG
• Novo Nordisk A/S
• Thermo Fisher Scientific Inc
• Regeneron Pharmaceuticals Inc
• AstraZeneca plc
• Sanofi SA
• Abbott Laboratories
• Eli Lilly & Company
• Mylan N.V
• GlaxoSmithKline Plc
• Merck KgaA
• Among others

Strategic Developments

• In January 2022, GlaxoSmithKline announced that the U.S government would be purchasing sotrovimab, a monoclonal antibody for early treatment t of Covid-19.

Frequently Asked Questions About This Report